Common Contracts

Asset purchase and licensing agreement for stem cell technology

Asset Purchase Agreement • February 12th, 2022 • New York

• Contract Type
  Asset Purchase Agreement
• Filed
  February 12th, 2022
• Jurisdiction
  New York

This technology, which has generated preliminary data showing the potential to generate monocyte derived islet cells from peripheral blood mononuclear cells, was in early preclinical development at Opexa.

CONFIDENTIAL TREATMENT REQUESTED: INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND IS NOTED WITH “[*].” AN UNREDACTED VERSION OF THIS DOCUMENT HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASSET...

Asset Purchase Agreement • August 7th, 2009 • Opexa Therapeutics, Inc. • Pharmaceutical preparations • New York

• Contract Type
  Asset Purchase Agreement
• Filed
  August 7th, 2009
• Company
  Opexa Therapeutics, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This ASSET PURCHASE AGREEMENT (this “Agreement”) is dated as of August 6, 2009 (the “Effective Date”), by and between Novartis Institutes for BioMedical Research, Inc., a Delaware corporation (“Novartis”) and Opexa Therapeutics, Inc., a Texas corporation (the “Company”).